Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Michael Behrens

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Plos One|April 25, 2012
The spatial distribution of LGR5+ cells correlates with gastric cancer progressionEva Simon, Diana Petke, Christine Böger, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|September 16, 2015
Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for StandardizationMicaela Mathiak, Viktoria S Warneke, Hans-Michael Behrens, et al.
Translational Oncology|December 23, 2019
Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve CohortHauke Schoop, Anna Bregenzer, Christine Halske, et al.
Journal of Cancer Research and Clinical Oncology|June 13, 2023
LAG3 in gastric cancer: it's complicatedDita Ulase, Hans-Michael Behrens, Sandra Krüger, et al.
BMC Cancer|April 24, 2026
MYC amplification is common in cancer of the stomach and gastroesophageal junction, correlates with male sex and reduced response to neoadjuvant therapyOle Biegler, Hans-Michael Behrens, Jochen Haag, et al.
British Journal of Cancer|November 8, 2022
Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinomaMagnus Kock Am Brink, Laura Sophie Dunst, Hans-Michael Behrens, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 16, 2014
Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancerChristine Böger, Viktoria S Warneke, Hans-Michael Behrens, et al.
Disease Markers|December 13, 2019
Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy ResponseAntonia Freiin Grote, Christine Halske, Hans-Michael Behrens, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 16, 2025
Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-worldSteffen M Heckl, Hans-Michael Behrens, Ulrike Ebert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2011
Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging systemViktoria S Warneke, Hans-Michael Behrens, Jörg T Hartmann, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Plos One|April 25, 2012
The spatial distribution of LGR5+ cells correlates with gastric cancer progressionEva Simon, Diana Petke, Christine Böger, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|September 16, 2015
Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for StandardizationMicaela Mathiak, Viktoria S Warneke, Hans-Michael Behrens, et al.
Translational Oncology|December 23, 2019
Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve CohortHauke Schoop, Anna Bregenzer, Christine Halske, et al.
Journal of Cancer Research and Clinical Oncology|June 13, 2023
LAG3 in gastric cancer: it's complicatedDita Ulase, Hans-Michael Behrens, Sandra Krüger, et al.
BMC Cancer|April 24, 2026
MYC amplification is common in cancer of the stomach and gastroesophageal junction, correlates with male sex and reduced response to neoadjuvant therapyOle Biegler, Hans-Michael Behrens, Jochen Haag, et al.
British Journal of Cancer|November 8, 2022
Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinomaMagnus Kock Am Brink, Laura Sophie Dunst, Hans-Michael Behrens, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 16, 2014
Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancerChristine Böger, Viktoria S Warneke, Hans-Michael Behrens, et al.
Disease Markers|December 13, 2019
Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy ResponseAntonia Freiin Grote, Christine Halske, Hans-Michael Behrens, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 16, 2025
Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-worldSteffen M Heckl, Hans-Michael Behrens, Ulrike Ebert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2011
Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging systemViktoria S Warneke, Hans-Michael Behrens, Jörg T Hartmann, et al.
Pageof 7